We used a central computerised phone or interactive web system to randomly assign ( 1:1 ) patients at high risk of morbidity and mortality from 80 hospital or cardiac surgery centres in 18 countries undergoing cardiac surgery with the use of cardiopulmonary bypass to receive either methylprednisolone ( 250 mg at anaesthetic induction and 250 mg at initiation of cardiopulmonary bypass ) or placebo .